PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.

Autor:	Taskén K; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. kjetil.tasken@medisin.uio.no., F Haj Mohammad S; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. s.f.haj_mohammad@lumc.nl., Fagereng GL; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway. gfageren@ous-hf.no., Sørum Falk R; Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. rs@ous-hf.no., Helland Å; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway. aslaug.helland@medisin.uio.no., Barjesteh van Waalwijk van Doorn-Khosrovani S; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands; CZ Health Insurance, Tilburg, The Netherlands. sahar.van.waalwijk@cz.nl., Steen Carlsson K; Swedish Institute for Health Economics, Lund, Sweden. katarina.steen_carlsson@ihe.se., Ryll B; Stockholm School of Economics Institute for Research, Stockholm, Sweden. Bettina.Ryll@hhs.se., Jalkanen K; Clinical Trial Unit, Comprehensive Cancer Centre, Helsinki University Hospital, Helsinki, Finland. katriina.jalkanen@hus.fi., Edsjö A; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Region Skåne, Malmö, Sweden. anders.edsjo@skane.se., Russnes HG; Institute for Cancer Research, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Pathology, Oslo University Hospital, Oslo, Norway. h.e.g.russnes@medisin.uio.no., Lassen U; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. ulrik.lassen@regionh.dk., Hallersjö Hult E; Stockholm School of Economics Institute for Research, Stockholm, Sweden. ebba.hallersjo.hult@hhs.se., Lugowska I; Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland. Iwona.Lugowska@nio.gov.pl., Blay JY; Centre Léon Bérard, Lyon, France. jean-yves.blay@lyon.unicancer.fr., Verlingue L; Centre Léon Bérard, Lyon, France. Loic.VERLINGUE@lyon.unicancer.fr., Abel E; Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden. edvard.abel@vgregion.se., Lowery MA; Trinity St James Cancer Institute, Trinity College, Dublin, Ireland. MLOWERY@tcd.ie., Krebs MG; Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. matthew.krebs@nhs.net., Staal Rohrberg K; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. kristoffer.staal.rohrberg@regionh.dk., Ojamaa K; Hematology-Oncology Clinic at Tartu University Hospital, Tartu, Estonia. Kristiina.Ojamaa@kliinikum.ee., Oliveira J; Instituto Português de Oncologia do Porto FG, Porto, Portugal. julio.oliveira@ipoporto.min-saude.pt., Verheul HMW; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. h.verheul@erasmusmc.nl., Voest EE; Department of Molecular Oncology & Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands. e.voest@nki.nl., Gelderblom H; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. a.j.gelderblom@lumc.nl.
Jazyk:	angličtina
Zdroj:	Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2024 May 23; Vol. 63, pp. 385-391. Date of Electronic Publication: 2024 May 23.
DOI:	10.2340/1651-226X.2024.34791
Abstrakt:	Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. Patients and Methods: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe. Results: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. Conclusion: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. Conclusion: European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu